RU2683823C2 - Препарат гормона роста человека длительного типа - Google Patents

Препарат гормона роста человека длительного типа Download PDF

Info

Publication number
RU2683823C2
RU2683823C2 RU2016113684A RU2016113684A RU2683823C2 RU 2683823 C2 RU2683823 C2 RU 2683823C2 RU 2016113684 A RU2016113684 A RU 2016113684A RU 2016113684 A RU2016113684 A RU 2016113684A RU 2683823 C2 RU2683823 C2 RU 2683823C2
Authority
RU
Russia
Prior art keywords
long
growth hormone
human growth
acting
conjugate
Prior art date
Application number
RU2016113684A
Other languages
English (en)
Russian (ru)
Other versions
RU2016113684A (ru
RU2016113684A3 (es
Inventor
Хва Поунг РИМ
Хьюн Ок Ким
Хо Тэк ИМ
Сан Юн Ким
Хьюнг Кю Лим
Сан Мин Бэ
Се Чан КВОН
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of RU2016113684A publication Critical patent/RU2016113684A/ru
Publication of RU2016113684A3 publication Critical patent/RU2016113684A3/ru
Application granted granted Critical
Publication of RU2683823C2 publication Critical patent/RU2683823C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
RU2016113684A 2013-09-27 2014-09-26 Препарат гормона роста человека длительного типа RU2683823C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130115177 2013-09-27
KR10-2013-0115177 2013-09-27
PCT/KR2014/009059 WO2015046974A1 (ko) 2013-09-27 2014-09-26 지속형 인간 성장 호르몬 제제

Publications (3)

Publication Number Publication Date
RU2016113684A RU2016113684A (ru) 2017-11-01
RU2016113684A3 RU2016113684A3 (es) 2018-06-28
RU2683823C2 true RU2683823C2 (ru) 2019-04-02

Family

ID=52743982

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016113684A RU2683823C2 (ru) 2013-09-27 2014-09-26 Препарат гормона роста человека длительного типа

Country Status (15)

Country Link
US (2) US10987425B2 (es)
EP (2) EP3050559B1 (es)
JP (1) JP6549104B2 (es)
KR (1) KR102276304B1 (es)
CN (2) CN105848645A (es)
AR (1) AR097840A1 (es)
AU (1) AU2014329003A1 (es)
BR (1) BR112016006455A2 (es)
CA (1) CA2925416A1 (es)
HK (1) HK1225976A1 (es)
IL (1) IL244769A0 (es)
MX (1) MX2016003705A (es)
RU (1) RU2683823C2 (es)
TW (1) TW201605468A (es)
WO (1) WO2015046974A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
SG10202107752PA (en) * 2014-03-31 2021-09-29 Hanmi Pharmaceutical Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
KR20170079409A (ko) * 2015-12-30 2017-07-10 한미약품 주식회사 지속형 인간 성장 호르몬 결합체의 신규 액상 제제
CN106256835A (zh) * 2016-08-19 2016-12-28 安源医药科技（上海）有限公司 高糖基化人生长激素融合蛋白及其制备方法与用途
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
IL298396A (en) * 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd A liquid formulation of a long-acting conjugate of a glucagon derivative
CN115845032A (zh) * 2022-10-28 2023-03-28 深圳科兴药业有限公司 生长激素fc融合蛋白注射液及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019776A1 (en) * 1992-04-03 1993-10-14 Kabi Pharmacia Ab Protein formulation comprising growth hormone
RU2191029C2 (ru) * 1996-02-12 2002-10-20 Си Эс Эл ЛИМИТЕД Композиция стабилизированного гормона роста и способ ее приготовления
RU2229288C2 (ru) * 1995-07-27 2004-05-27 Джинентех, Инк. Стабильная изотоническая лиофилизированная протеиновая композиция
RU2436796C2 (ru) * 2006-05-30 2011-12-20 Дженентек, Инк. Антитела и иммуноконъюгаты и их применения
WO2012008779A2 (en) * 2010-07-14 2012-01-19 Hanmi Holdings Co., Ltd. A liquid formulation of long-acting human growth hormone conjugate

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719479B1 (fr) 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JPH10265404A (ja) 1996-02-02 1998-10-06 Mitsui Chem Inc ヒト成長ホルモンを含有する医薬製剤
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
SE9704405D0 (sv) 1997-11-28 1997-11-28 Pharmacia & Upjohn Ab New syringe
RU2190129C2 (ru) 2000-10-17 2002-09-27 Открытое акционерное общество "Павловский машиностроительный завод "Восход" Резервированный электрогидравлический привод
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
ES2383691T3 (es) 2003-12-23 2012-06-25 Pharmacia Corporation Formulación líquida estable de hormonas de crecimiento
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
JP4283776B2 (ja) 2005-03-07 2009-06-24 ラボラトワール セローノ ソシエテ アノニム Ｈｇｈ含有医薬組成物
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
AU2006295340B2 (en) * 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
ES2667025T3 (es) 2009-12-15 2018-05-09 Ascendis Pharma Endocrinology Division A/S Composición seca de hormona de crecimiento unida transitoriamente a un portador de polímero
EP2606908A1 (en) 2011-12-19 2013-06-26 Ipsen Pharma S.A.S. Novel pharmaceutical composition for a long acting growth hormone fusion protein (LAGH)
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019776A1 (en) * 1992-04-03 1993-10-14 Kabi Pharmacia Ab Protein formulation comprising growth hormone
RU2229288C2 (ru) * 1995-07-27 2004-05-27 Джинентех, Инк. Стабильная изотоническая лиофилизированная протеиновая композиция
RU2191029C2 (ru) * 1996-02-12 2002-10-20 Си Эс Эл ЛИМИТЕД Композиция стабилизированного гормона роста и способ ее приготовления
RU2436796C2 (ru) * 2006-05-30 2011-12-20 Дженентек, Инк. Антитела и иммуноконъюгаты и их применения
WO2012008779A2 (en) * 2010-07-14 2012-01-19 Hanmi Holdings Co., Ltd. A liquid formulation of long-acting human growth hormone conjugate

Also Published As

Publication number Publication date
IL244769A0 (en) 2016-04-21
JP6549104B2 (ja) 2019-07-24
EP3050559B1 (en) 2020-06-03
KR20150035681A (ko) 2015-04-07
AR097840A1 (es) 2016-04-20
RU2016113684A (ru) 2017-11-01
AU2014329003A1 (en) 2016-05-12
US10987425B2 (en) 2021-04-27
EP3689335A1 (en) 2020-08-05
CN114288254A (zh) 2022-04-08
EP3050559A4 (en) 2017-05-31
US20160213789A1 (en) 2016-07-28
KR102276304B1 (ko) 2021-07-14
RU2016113684A3 (es) 2018-06-28
TW201605468A (zh) 2016-02-16
CN105848645A (zh) 2016-08-10
CA2925416A1 (en) 2015-04-02
US20210138070A1 (en) 2021-05-13
EP3050559A1 (en) 2016-08-03
HK1225976A1 (zh) 2017-09-22
JP2016533345A (ja) 2016-10-27
WO2015046974A1 (ko) 2015-04-02
MX2016003705A (es) 2016-05-16
BR112016006455A2 (pt) 2017-08-01

Similar Documents

Publication Publication Date Title
RU2683823C2 (ru) Препарат гормона роста человека длительного типа
TWI459961B (zh) 長效人類生長激素共軛物之液態配方
RU2519031C1 (ru) Жидкие препаративные формы для длительно действующего конъюгата g-csf
US20180344866A1 (en) Liquid formulation of highly concentrated long-acting human growth hormone conjugate
US20190022183A1 (en) A novel liquid formulation of long-acting human growth hormone conjugate

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200927